Hematopoietic and Lymphoid System Neoplasm Withdrawn Phase 2 Trials for Cyclophosphamide (DB00531)

Indication	Status	Phase
DBCOND0132171 (Hematopoietic and Lymphoid System Neoplasm)	Withdrawn	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT03602898	Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation	Treatment	Busulfan (DB01008) Cyclophosphamide (DB00531) Cyclosporine (DB00091) Fludarabine (DB01073) Methopterin (DB16620) Methotrexate (DB00563) Tacrolimus (DB00864)